Synact Pharma Ab Stock Net Income
| SYNACT Stock | 22.20 0.40 1.83% |
By evaluating key metrics such as revenue growth, profitability, cash flow trends, and balance sheet strength, investors can better assess SynAct Pharma's long-term financial health and intrinsic value.
SynAct |
SynAct Pharma AB Company Net Income Analysis
SynAct Pharma's Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Current SynAct Pharma Net Income | (76.7 M) |
Most of SynAct Pharma's fundamental indicators, such as Net Income, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, SynAct Pharma AB is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, SynAct Pharma AB reported net income of (76.7 Million). This is much lower than that of the sector and significantly lower than that of the Net Income industry. The net income for all Sweden stocks is notably higher than that of the company.
SynAct Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses SynAct Pharma's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of SynAct Pharma could also be used in its relative valuation, which is a method of valuing SynAct Pharma by comparing valuation metrics of similar companies.SynAct Pharma is currently under evaluation in net income category among its peers.
SynAct Fundamentals
| Return On Equity | -1.49 | |||
| Return On Asset | -0.81 | |||
| Current Valuation | 2.08 B | |||
| Shares Outstanding | 31.82 M | |||
| Shares Owned By Insiders | 36.67 % | |||
| Shares Owned By Institutions | 2.41 % | |||
| Price To Book | 26.57 X | |||
| EBITDA | (76.62 M) | |||
| Net Income | (76.7 M) | |||
| Book Value Per Share | 2.82 X | |||
| Cash Flow From Operations | (65 M) | |||
| Target Price | 120.0 | |||
| Beta | 0.69 | |||
| Market Capitalization | 2.42 B | |||
| Total Asset | 38.37 M | |||
| Z Score | -3.3 | |||
| Net Asset | 38.37 M |
About SynAct Pharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze SynAct Pharma AB's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of SynAct Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of SynAct Pharma AB based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Other Information on Investing in SynAct Stock
SynAct Pharma financial ratios help investors to determine whether SynAct Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in SynAct with respect to the benefits of owning SynAct Pharma security.